Evidence map›Paper›PMID 25977900›Full record

ArticleOncolytic virotherapy2012

Oncolytic virotherapy for ovarian cancer.

Shoudong Li, Jessica Tong, Masmudur M Rahman, Trevor G Shepherd, Grant McFadden

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncolytic virotherapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Shoudong LiDepartment of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL, USA.
Jessica TongDepartment of Anatomy and Cell Biology, University of Western Ontario, London, Ontario, Canada ; Translational Ovarian Cancer Research Program, London Health Sciences Centre, London, Ontario, Canada.
Masmudur M RahmanDepartment of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL, USA.
Trevor G ShepherdDepartment of Anatomy and Cell Biology, University of Western Ontario, London, Ontario, Canada ; Translational Ovarian Cancer Research Program, London Health Sciences Centre, London, Ontario, Canada.
Grant McFaddenDepartment of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL, USA.
University of Florida · USWestern University · CALondon Health Sciences Centre · CA

Funding

Studies in Poxvirus Host Range Genes and TropismR01AI080607 · NIAID · UNIVERSITY OF FLORIDA · PI RAHMAN, MASMUDUR MOHAMMED · 2009 to 2025
$5.6M
Myxoma Virus (MV) Oncolysis for treating human cancerR01CA138541 · NCI · UNIVERSITY OF FLORIDA · PI MCFADDEN, GRANT · 2010 to 2014
$1.5M
Virotherapy for pancreatic cancer with wildtype and armed Myxoma virusesR21CA149869 · NCI · UNIVERSITY OF FLORIDA · PI MCFADDEN, GRANT · 2011 to 2012
$351k
NCI NIH HHS R01 CA138541NCI NIH HHS R21 CA149869NIAID NIH HHS R01 AI080607
6 · The paper itself

Abstract

In the past two decades, more than 20 viruses with selective tropism for tumor cells have been developed as oncolytic viruses (OVs) for treatments of a variety of malignancies. Of these viruses, eleven have been tested in human ovarian cancer models in preclinical studies. So far, nine phase I or II clinical trials have been conducted or initiated using four different types of OVs in patients with recurrent ovarian cancers. In this article, we summarize the different OVs that are being assessed as therapeutics for ovarian cancer. We also present an overview of recent advances in identification of key genetic or immune-response pathways involved in tumorigenesis of ovarian cancer, which provides a better understanding of the tumor specificities and oncolytic properties of OVs. In addition, we discuss how next-generation OVs could be genetically modified or integrated into multimodality regimens to improve clinical outcomes based on recent advances in ovarian cancer biology.

Indexed as

clinical trialoncolytic virusovarian cancerpreclinical studiesvirotherapy

Identifiers

PMID25977900
PMCPMC4428588
OpenAlexW1967880037

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.